Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Meal replacement-based diet beneficial to T2D patients
A dietary pattern based on meal replacement (MR), compared with conventional diabetic diets (CDs), brings about improvements in glycaemic control and adipose indicators in patients with type 2 diabetes (T2D), according to a study.
Meal replacement-based diet beneficial to T2D patients
22 Nov 2023
HBV vaccine improves survival of patients with chronic liver disease
Vaccination against hepatitis B virus (HBV) results in meaningful improvements in survival among patients with different kinds of chronic liver diseases, suggests a study presented at AASLD 2023.
HBV vaccine improves survival of patients with chronic liver disease
22 Nov 2023
Modified PDT on par with isotretinoin therapy for moderate-to-severe acne vulgaris
The modified red light 5-aminolevulinic acid photodynamic therapy (M-PDT) delivers a faster onset of improvement, similar overall efficacy, good tolerability, and comparable durability of response when compared with low-dose isotretinoin (ISO) therapy in patients with moderate-to-severe acne vulgaris, reports a study.
Modified PDT on par with isotretinoin therapy for moderate-to-severe acne vulgaris
22 Nov 2023
Saline rinses may help prevent COVID-19 hospitalization
A study presented at ACAAI 2023 demonstrated the potential of simple home remedies such as gargling and nasal rinsing with saltwater in cutting COVID-19 hospitalization rates.
Saline rinses may help prevent COVID-19 hospitalization
22 Nov 2023
Thromboembolism rate lower than expected in Chinese patients with pancreatic cancer
Chinese patients with pancreatic cancer have a lower incidence of thromboembolism compared with Western populations, and thromboembolism does not affect overall survival (OS), researchers from the Chinese University of Hong Kong (CUHK) have reported.
Thromboembolism rate lower than expected in Chinese patients with pancreatic cancer
22 Nov 2023
More evidence support ticagrelor monotherapy after <1-month DAPT in ACS
Dropping aspirin after <1 month of dual antiplatelet therapy (DAPT) with ticagrelor is superior to continuing both drugs through 12 months in patients with acute coronary syndrome (ACS) implanted with drug-eluting stents in the T-PASS trial.
